Proteins in West Nile Virus (WNV)

WNV is an RNA virus. It has three structural proteins: the capsid (C) protein, the envelope (E) protein, and the membrane (M) protein. Among them, the E protein is a glycoprotein. It stimulates the body to produce large amounts of neutralizing antibodies that mediate receptor binding, cell fusion, and viral aggregation. It consists of three structural domains, where the structural domain III (DIII) is the region with the best immunogenicity. It is found that E DIII induces more Th1 immune responses. The addition of Adjuvant further enhances anti-E DIII antibody titers. E DIII protein has the potential to develop a WNV protein vaccine.

WNV Vaccine Development Service at CD BioGlyco

CD BioGlyco aims to provide efficient WNV vaccine development services. Conventional vaccines may cause large immune responses. Recombinant glycoprotein vaccines avoid these problems. We construct different forms of E protein and E DIII recombinant protein. We screen the best form of E protein and E DIII protein by comparison.

We design protein vaccines by immunoinformatics. After constructing recombinant expression vectors for E and E DIII proteins, we express them through eukaryotic expression systems such as Plants, Mammals, and Escherichia coli expression systems. We have highly efficient expression vectors, which can greatly shorten the experimental period. We also have a wide variety of E. coli cell lines, which can provide high-quality glycoprotein expression services. Meanwhile, we optimize the published purification and identification methods to obtain purified E protein and E DIII protein. We have a comprehensive vaccine evaluation system. Our tests include cell proliferation assay, enzyme-linked immunospot assay (ELISA), cytokine assay, and so on. We will design complete experiments to study vaccine-mediated immune responses.

Fig.1 The standard process of WNV vaccine development. (CD BioGlyco)

Advantages of Us

• We have a wide range of recombinant protein expression systems, including mammalian, plant, E. coli, etc., which can produce high-quality recombinant proteins.
• We have rich experience in immunoassays and provide a wide range of vaccine cellular immunoassay evaluation services. All experimental methods are rigorously validated.
• Our mammalian transient expression systems have a high expression success rate and provide flexible services to meet the needs of different experiments, including glycosylation analysis, tag removal, and so on.

CD BioGlyco's sugar-related Vaccine Development Platforms cover a wide range of topics, including Carbohydrate-based Vaccine Development, Glycopeptide-based Vaccine Development, and more. We aim to facilitate vaccine development. If you are interested in our vaccine development services, please feel free to contact us.

Reference

1. Chu, J.H.; et al. Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection. J Immunol. 2007, 178(5): 2699-2705.